Varian forms global council for RapidArc growth:
This article was originally published in Clinica
Executive Summary
As part of the ongoing development of its RapidArc radiotherapy system, Varian Medical Systems has formed a council of cancer centres in North America and Europe to explore further clinical applications of the technology. The council members will meet regularly with Varian's engineers in Switzerland, Finland and the US, to collaborate on future improvements to the system. RapidArc is a volumetric arc therapy system designed to deliver image-guided, intensity-modulated radiation therapy (IMRT) two to eight times faster than conventional IMRT or helical treatments. It was cleared by the US FDA in January (see Clinica No 1289, p 18) and first shipments of the product are expected to begin in April this year.
You may also be interested in...
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.